Oral Bioavailability Equipment & Supplies
151 equipment items found
by:Alfa Cytology based inU.S. VIRGIN ISLANDS
Bis-Pro-5FU is a 5-FU precursor that confers oral bioavailability and improves the safety of 5-fluorouracil (5-FU) chemotherapy regimens. 5-FU is an antitumor antimetabolite that is widely used in colorectal and pancreatic cancer research. ...
Manufactured by:TargetMol Chemicals Inc. based inWellesley Hills, MASSACHUSETTS (USA)
GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, with IC50=0.6-2.0 nM for SIK1, SIK2 and SIK3, and exhibits anti-inflammatory and immunomodulatory activity in both human primary myeloid cells and mouse ...
Manufactured by:EndoLogic LLC based inClifton, NEW JERSEY (USA)
Renzapride is best suited as a treatment of Diabetic Gastroparesis, a condition with a significant unmet treatment options. In the numerous trials that have been done using Renzapride more than 5000 patients have been treated with Renzapride. An extensive cardiac safety evaluation under the FDA mandated Thorough QT trial has shown that Renzapride does not have any cardiac safety ...
Manufactured by:LTS Lohmann Therapie-Systeme AG based inAndernach, GERMANY
LTS Lohmann Therapie-Systeme AG specializes in transdermal therapeutic systems (TTS) that enhance patient outcomes by ensuring controlled and balanced drug release, reducing peak concentrations, and mitigating common side effects such as nausea and vomiting. These systems provide a non-invasive delivery route, suitable for active substances with low oral bioavailability, ensuring improved ...
Manufactured by:Shifa Biomedical Corporation based inMalvern, PENNSYLVANIA (USA)
LDLR is a cell-surface receptor that binds LDL-C and carries it into cells to the endosome for degradation and thus reduces the plasma level of LDL-C (Figure 1). However, PCSK9 controls the degradation of the LDLR in the liver (Figure 1) and thereby contributes to cholesterol ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
An orally bioavailable nanoformulation of betulinic acid that works as an HIV maturation inhibitor. APH-0202 is an oral nanoformulation containing betulinic acid. A pentacyclic triterpene, betulinic acid is a component of the bark of the white birch tree, Betula alba. Phospholipid nanosomes can be utilized to enhance the formulation and efficacy of betulinic acid. Oral bioavailability can be ...
Manufactured by:Triastek based inNanjing, CHINA
Triastek's 3DuS-GR technology is designed for targeted drug delivery to the stomach, allowing the product to remain in the gastric region for a pre-determined duration. This system is capable of customizing drug release profiles to achieve either extended-release or pulsatile-release, thereby potentially enhancing the absorption of active pharmaceutical ingredients and increasing drug efficacy. ...
Manufactured by:ENB Therapeutics based inNew York, NEW YORK (USA)
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which is required for T-cells to leave the circulation and infiltrate the tumor. Activated T cells are then able to infiltrate the tumor and kill ...
Manufactured by:Skyepharma Production SAS based inSaint-Quentin-Fallavier, FRANCE
Soctec® was developed for drugs that need to be retained in the stomach for an extended period of time to then being slowly released either for a local effect in the stomach or for absorption in the upper intestine. This is a versatile extended release gastro-retentive capsule platform technology designed to overcome many of the limitations of alternative systems while improving oral ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies, and ...
Manufactured by:SQ Innovation, Inc. based inBurlington, MASSACHUSETTS (USA)
Lasix ONYU is an advanced prescription drug-device combination designed specifically for the treatment of edema in adults suffering from chronic heart failure. This innovative product represents a shift from traditional oral and intravenous methods by introducing a high-concentration formulation of furosemide for subcutaneous infusion. Each prefilled cartridge within the device delivers 80 mg of ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Poor Solubility and Associated Formulation and Bioavailability Difficulties. Although paclitaxel is an effective anticancer drug, its solubility is low (~ 0.4 µg/mL), which limits its medical utility to intravenous applications. Docetaxel (Taxotere®) was developed as a paclitaxel derivative having improved water solubility; its solubility, however, is only ~ 14 µg/mL. Several ...
Manufactured by:Scopus BioPharma based inNew York, NEW YORK (USA)
We are developing MRI-1867, our licensed rationally designed, orally available, dual-action, hybrid, small molecule that is an inverse agonist of the CB1 receptor, as well as an inhibitor of the iNOS ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
NBI 35965 methanesulfonate is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki value of 4 nM and a pKi value of 8.5. NBI 35965 methanesulfonate does not inhibit CRF2. NBI 35965 methanesulfonate reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC50 values of 7.1 and 6.9, respectively. NBI ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Irdabisant (CEP-26401) is a selective, orally active and blood-brain barrier (BBB) penetrant histamine H3 receptor (H3R) inverse agonist/inverse agonist with Ki values of 7.2 nM and 2.0 nM for rat H3R and human H3R, respectively. Irdabisant has relatively low inhibitory activity against hERG current with an IC50 of 13.8 μM. Irdabisant has cognition-enhancing and wake-promoting activities in the ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3, with IC50s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC50 of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 µM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Schisandrol B (Gomisin-A) is a major active constituent of Schisandra chinensis with hepato-protective effects. Schisandrol B inhibits reactive oxygen species (ROS) production. Schisandrol B inhibits the activity of P-glycoprotein and CYP3A and also has anti-inflammatory, anti-diabetic and antioxidant ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
APD668 is a potent, selective and orally active agonist of G-protein coupled receptor GPR119, with EC50s of 2.7 nM and 33 nM for hGPR119 and rGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception of CYP2C9 (Ki=0.1 μM). APD668 can be used for the research of steatohepatitis and ...